Citigroup
RYTM icon

Citigroup’s Rhythm Pharmaceuticals RYTM Stock Holding History

Citigroup’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100,000
Closed -$1.78M – 5702
2023
Q1 		$1.78M Buy
100,000
+10,000
+11% +$251K ﹤0.01% 2105
2022
Q4 		$2.62M Hold
90,000
– – ﹤0.01% 1843
2022
Q3 		$2.21M Buy
+90,000
New +$1.67M ﹤0.01% 2072

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Citigroup's RYTM Position: Q1 2026 in Review

Citigroup reduced its Rhythm Pharmaceuticals (RYTM) stake by 3% in Q1 2026, selling an estimated $37.3K and leaving 12,336 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3073.

Citigroup first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $8.26M in Q1 2024. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Citigroup held 12,336 shares of Rhythm Pharmaceuticals worth $1.07M as of Q1 2026.
  • Citigroup sold 384 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $37.3K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3073 holding.
  • Citigroup first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Citigroup's Rhythm Pharmaceuticals position peaked at $8.26M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.